Daunorubicin
 | |
|---|---|
| Systematic (IUPAC) name | |
| (8S,10S)-8-acetyl-10-[(2S,4S,5S,6S)- 4-amino-5-hydroxy-6-methyl-oxan- 2-yl]oxy-6,8,11-trihydroxy-1-methoxy- 9,10-dihydro-7H-tetracene-5,12-dione | |
| Identifiers | |
| CAS number | 20830-81-3 |
| ATC code | L01DB02 |
| PubChem | CID 30323 |
| DrugBank | APRD00521 |
| ChemSpider | 28163 |
| UNII | ZS7284E0ZP |
| ChEMBL | CHEMBL178 |
| Chemical data | |
| Formula | C27H29NO10 |
| Mol. mass | 527.52 g/mol 563.99 g/mol (HCl salt) |
| SMILES | eMolecules & PubChem |
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Half-life | 26.7 hours (metabolite) |
| Excretion | Biliary and urinary |
| Therapeutic considerations | |
| Pregnancy cat. | D (U.S.) |
| Legal status | ? |
| Routes | Exclusively intravenous. Causes severe necrosis if administered intramuscularly or subcutaneously |
 (what is this?) (verify) | |
Daunorubicin or daunomycin (daunomycin cerubidine) is chemotherapeutic of the anthracycline family that is given as a treatment for some types of cancer. It is most commonly used to treat specific types of leukaemia (acute myeloid leukemia and acute lymphocytic leukemia). It was initially isolated from .
A liposomal formulation of daunorubicin is marketed in the United States as DaunoXome.
History
In the 1950s, an Italian research company, Farmitalia Research Laboratories, began an organized effort to isolate anticancer compounds from soil-based microbes. A soil sample was isolated from the area surrounding the Castel del Monte, a 13th century castle in Apulia. A new strain of Streptomyces peucetius which produced a red pigment was isolated, and an antibiotic was produced from this bacterium that was found to have good activity against murine tumors. Since a group of French researchers discovered the same compound at about the same time, the two teams named the compound daunorubicin, combining the name Dauni, a pre-Roman tribe that occupied the area of Italy where the compound was isolated, with the French word for ruby, rubis, describing the color. Clinical trials began in the 1960s, and the drug saw success in treating acute leukemia and lymphoma. However, by 1967, it was recognized that daunorubicin could produce fatal cardiac toxicity.
Uses
It slows or stops the growth of cancer cells in the body. Treatment is usually together with other chemotherapy drugs (such as cytarabine), and its administration depends on the type of tumor and the degree of response.
In addition to its major use in treating AML, daunorubicin is also used to treat neuroblastoma. Daunorubicin has been used with other chemotherapy agents to treat the blastic phase of chronic myelogenous leukemia.
Daunorubicin is also used as the starting material for semi-synthetic manufacturing of doxorubicin, epirubicin and idarubicin.
Mode of action
On binding to DNA, daunomycin intercalates, with its daunosamine residue directed toward the minor groove. It has the highest preference for two adjacent G/C base pairs flanked on the 5' side by an A/T base pair. Daunomycin effectively binds to every 3 base pairs and induces a local unwinding angle of 11, but negligible distortion of helical conformation.
Route of administration
Daunorubicin should only be administered in a rapid intravenous infusion. It should not be administered intramuscularly or subcutaneously, since it may cause extensive tissue necrosis. It should also never be administered intrathecally (into the spinal canal), as this will cause extensive damage to the nervous system and may lead to death.
References
External links
Retrieved from : http://en.wikipedia.org/wiki/Daunorubicin
